WO2015131858A3 - Péptidos horquilla beta con propiedades antivirales contra el virus dengue - Google Patents

Péptidos horquilla beta con propiedades antivirales contra el virus dengue Download PDF

Info

Publication number
WO2015131858A3
WO2015131858A3 PCT/CU2015/000002 CU2015000002W WO2015131858A3 WO 2015131858 A3 WO2015131858 A3 WO 2015131858A3 CU 2015000002 W CU2015000002 W CU 2015000002W WO 2015131858 A3 WO2015131858 A3 WO 2015131858A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
dengue virus
properties against
viral properties
peptides
Prior art date
Application number
PCT/CU2015/000002
Other languages
English (en)
French (fr)
Other versions
WO2015131858A2 (es
Inventor
Glay Chinea Santiago
Vivian Huerta Galindo
Alejandro Miguel MARTÍN DUNN
Hilda Elisa GARAY PÉREZ
Osvaldo Reyes Acosta
Viviana FALCÓN CAMA
Dianne PUPO GÓMEZ
Alexis YERO DÍAZ
Gabriel Jesús MÁRQUEZ PERERA
Mónica SARRÍA NÚÑEZ
Osmany Guirola Cruz
Rocio GARATEIX SUÁREZ
Karen ALVAREZ PÉREZ
Sonia González Blanco
Mariela VÁZQUEZ CASTILLO
Luis Javier GONZÁLEZ LÓPEZ
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2940078A priority Critical patent/CA2940078C/en
Application filed by Centro De Ingenieria Genetica Y Biotecnologia filed Critical Centro De Ingenieria Genetica Y Biotecnologia
Priority to BR112016019672-4A priority patent/BR112016019672B1/pt
Priority to AU2015226580A priority patent/AU2015226580B2/en
Priority to MX2016011420A priority patent/MX363745B/es
Priority to JP2016555504A priority patent/JP6854644B2/ja
Priority to ES15718758T priority patent/ES2733648T3/es
Priority to CN201580011814.8A priority patent/CN106132981B/zh
Priority to KR1020167026665A priority patent/KR102325400B1/ko
Priority to US15/119,058 priority patent/US9896482B2/en
Priority to EP15718758.4A priority patent/EP3115056B1/en
Publication of WO2015131858A2 publication Critical patent/WO2015131858A2/es
Publication of WO2015131858A3 publication Critical patent/WO2015131858A3/es
Priority to PH12016501715A priority patent/PH12016501715B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con péptidos sintéticos, estructuralmente constreñidos, que han sido optimizados para la formación de estructura horquilla beta. Dichos péptidos son capaces de inhibir o atenuar la infección por el virus Dengue (DENV). La invención incluye también composiciones farmacéuticas que contienen estos péptidos sintéticos, las que son útiles para la prevención y/o el tratamiento de las infecciones causadas por DENV. De igual forma, la invención provee un método de tratamiento de las infecciones causadas por este virus.
PCT/CU2015/000002 2014-03-03 2015-02-26 Péptidos horquilla beta con propiedades antivirales contra el virus dengue WO2015131858A2 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES15718758T ES2733648T3 (es) 2014-03-03 2015-02-26 Péptidos de horquilla beta que tienen propiedades antivirales contra el virus del Dengue
BR112016019672-4A BR112016019672B1 (pt) 2014-03-03 2015-02-26 Peptídeos de grampo beta com propriedades antivirais contra o vírus da dengue, composição farmacêutica e seus usos
AU2015226580A AU2015226580B2 (en) 2014-03-03 2015-02-26 Beta-hairpin peptides having anti-viral properties against the dengue virus
MX2016011420A MX363745B (es) 2014-03-03 2015-02-26 Peptidos horquilla beta con propiedades antivirales contra el virus dengue.
JP2016555504A JP6854644B2 (ja) 2014-03-03 2015-02-26 デングウイルスに対する抗ウイルス特性を有するベータヘアピンペプチド
CA2940078A CA2940078C (en) 2014-03-03 2015-02-26 Beta hairpin peptides having anti-viral properties against the dengue virus
CN201580011814.8A CN106132981B (zh) 2014-03-03 2015-02-26 具有针对登革病毒的抗病毒特性的β-发夹肽
EP15718758.4A EP3115056B1 (en) 2014-03-03 2015-02-26 Beta-hairpin peptides having anti-viral properties against the dengue virus
US15/119,058 US9896482B2 (en) 2014-03-03 2015-02-26 Beta hairpin peptides having antiviral properties against Dengue virus
KR1020167026665A KR102325400B1 (ko) 2014-03-03 2015-02-26 뎅기열 바이러스에 대한 항바이러스 속성을 가진 베타 헤어핀 펩타이드
PH12016501715A PH12016501715B1 (en) 2014-03-03 2016-08-31 Beta hairpin peptides having antiviral properties against dengue virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUCU2014-0026 2014-03-03
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Publications (2)

Publication Number Publication Date
WO2015131858A2 WO2015131858A2 (es) 2015-09-11
WO2015131858A3 true WO2015131858A3 (es) 2015-10-29

Family

ID=53008223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2015/000002 WO2015131858A2 (es) 2014-03-03 2015-02-26 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Country Status (14)

Country Link
US (1) US9896482B2 (es)
EP (1) EP3115056B1 (es)
JP (1) JP6854644B2 (es)
KR (1) KR102325400B1 (es)
CN (1) CN106132981B (es)
AR (1) AR099563A1 (es)
AU (1) AU2015226580B2 (es)
CA (1) CA2940078C (es)
CU (1) CU20140026A7 (es)
ES (1) ES2733648T3 (es)
MX (1) MX363745B (es)
MY (1) MY181033A (es)
PH (1) PH12016501715B1 (es)
WO (1) WO2015131858A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124698A2 (es) * 2006-04-28 2007-11-08 Centro De Ingenieria Genetica Y Biotecnologia Métodos para tratar la infección por flavivirus, moléculas y usos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124698A2 (es) * 2006-04-28 2007-11-08 Centro De Ingenieria Genetica Y Biotecnologia Métodos para tratar la infección por flavivirus, moléculas y usos

Also Published As

Publication number Publication date
CU20140026A7 (es) 2015-11-27
MX363745B (es) 2019-04-01
EP3115056A2 (en) 2017-01-11
CN106132981B (zh) 2019-11-12
AU2015226580B2 (en) 2018-11-08
KR20160127097A (ko) 2016-11-02
AU2015226580A1 (en) 2016-09-15
CN106132981A (zh) 2016-11-16
BR112016019672A2 (pt) 2017-10-24
JP6854644B2 (ja) 2021-04-07
PH12016501715A1 (en) 2016-12-19
ES2733648T3 (es) 2019-12-02
CA2940078A1 (en) 2015-09-11
CA2940078C (en) 2020-11-17
AR099563A1 (es) 2016-08-03
EP3115056B1 (en) 2019-04-03
JP2017509619A (ja) 2017-04-06
US9896482B2 (en) 2018-02-20
KR102325400B1 (ko) 2021-11-12
US20170152290A1 (en) 2017-06-01
WO2015131858A2 (es) 2015-09-11
MX2016011420A (es) 2016-11-16
MY181033A (en) 2020-12-16
PH12016501715B1 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
WO2016109684A3 (en) Derivatives and methods of treating hepatitis b infections
WO2015197530A3 (en) Difluoromethyl-nicotinic-indanyl carboxamides
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX364942B (es) Peptidos antimicrobianos.
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
NZ741027A (en) Antimicrobial polymyxin derivative compounds
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
WO2017078577A3 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
WO2016146836A3 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
EP4268897A3 (en) Minocycline compounds for biodefense
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2015110915A3 (en) Retro-inverso analogs of spadin display increased antidepressant effects
MX2018001517A (es) Derivados sustituidos de guanidina.
WO2016100615A3 (en) Methods and composition for neutralization of influenza
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
EP3793539A4 (en) COMPOUNDS FOR THE TREATMENT OF DENGUE VIRUS INFECTIONS AND OTHER INFECTIONS
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
WO2016159640A3 (ko) 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2015131858A3 (es) Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15718758

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15119058

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2940078

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016501715

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2016555504

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/011420

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015226580

Country of ref document: AU

Date of ref document: 20150226

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167026665

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015718758

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015718758

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016019672

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016019672

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160825